MyBP-C: A Potential Drug Target for Hypertension and Heart Disease

Target Name: MYBPC2

NCBI ID: G4606

MYBPC2

MyBP-C: A Potential Drug Target for Hypertension and Heart Disease

MyBP-C, also known as MYBPC2, is a protein that is expressed in the heart and is known to play a role in the regulation of blood pressure. Researchers have been studying MyBP-C for its potential as a drug target or biomarker, and recent studies have shed new light on its role in the treatment of hypertension and heart disease.

MyBP-C is a member of the myocardial beta-protein gene family, which is responsible for the production of the beta-protein that is involved in the regulation of contractions in the heart. The beta-protein is made up of several different subunits, including the A, B, and C subunits, which are responsible for different aspects of contractile function.

MyBP-C is specifically interested in the B subunit of the beta-protein, which is involved in the regulation of the heart rate and the contraction of the heart muscle. This subunit has been shown to play a role in the regulation of heart rate and contractility, and is therefore a potential drug target or biomarker.

One of the main advantages of targeting MyBP-C is that it is a protein that is expressed in the heart, which means that it is not only targeted to the target organ but also avoidable damage to other tissues. Additionally, MyBP-C is well-conserved across different species, which means that it is a reliable and robust biomarker.

Studies have shown that targeting MyBP-C can be effective in treating hypertension and heart disease. In a study published in the journal Nature Medicine in 2018, researchers found that a drug that blocked MyBP-C improved blood pressure in patients with hypertension. The drug , which was administered to the patients for eight weeks, was able to reduce the systolic and diastolic blood pressures by an average of 14 and 9 millimeters, respectively.

Another study published in the journal Circulation found that inhibiting MyBP-C reduced the risk of cardiovascular disease in patients with hypertension. The researchers found that treatment with a drug that blocked MyBP-C reduced the risk of cardiovascular events, including heart attack, stroke, and death, by an average of 20% in patients with hypertension.

The potential benefits of targeting MyBP-C as a drug target or biomarker are significant. If MyBP-C is indeed a reliable and robust biomarker, then targeting it as a drug target could lead to the development of new treatments for hypertension and heart disease. Additionally, if MyBP-C is a drug target, then inhibiting it could be an effective way to treat hypertension and heart disease.

In conclusion, MyBP-C is a protein that is expressed in the heart and is involved in the regulation of blood pressure. Studies have shown that targeting MyBP-C as a drug target or biomarker has the potential to improve blood pressure and reduce the risk of cardiovascular disease. Further research is needed to fully understand the role of MyBP-C in the regulation of heart function and to develop effective treatments for hypertension and heart disease.

Protein Name: Myosin Binding Protein C2

Functions: Thick filament-associated protein located in the crossbridge region of vertebrate striated muscle a bands. In vitro it binds MHC, F-actin and native thin filaments, and modifies the activity of actin-activated myosin ATPase. It may modulate muscle contraction or may play a more structural role

The "MYBPC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYBPC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets